NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has a Return on Invested Capital (ROIC) of -44.65% and a Weighted Average Cost of Capital (WACC) of 5.55%, indicating it is not generating returns above its cost of capital.
Comparatively, ProKidney Corp. (NASDAQ:PROK) shows a positive ROIC of 16.10% and a WACC of 10.15%, demonstrating efficient capital utilization.
The negative ROIC to WACC ratios across peers in the biopharmaceutical industry highlight the sector’s high-risk, high-reward nature, with substantial upfront R&D investments required.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cardiovascular diseases. As a company in the early stages of development, NAMS invests heavily in research and development (R&D) to bring its innovative treatments to market. This investment strategy is common among its peers in the biopharmaceutical industry.
NAMS currently has a Return on Invested Capital (ROIC) of -44.65% and a Weighted Average Cost of Capital (WACC) of 5.55%. This results in a ROIC to WACC ratio of -8.05, indicating that the company is not generating returns above its cost of capital. This is typical for clinical-stage companies that are still in the process of developing their products and have not yet realized significant revenues.
In comparison, ProKidney Corp. (NASDAQ:PROK) demonstrates a positive ROIC of 16.10% and a WACC of 10.15%, resulting in a ROIC to WACC ratio of 1.59. This suggests that ProKidney is efficiently utilizing its capital to generate returns above its cost, making it the most efficient among the peers listed. This efficiency is a positive indicator for investors looking for companies with strong capital utilization.
Other peers such as Nuvalent, Inc. (NASDAQ:NUVL), PepGen Inc. (NASDAQ:PEPG), Tyra Biosciences, Inc. (NASDAQ:TYRA), and HilleVax, Inc. (NASDAQ:HLVX) also show negative ROIC to WACC ratios. For instance, HilleVax has a ROIC of -75.39% and a WACC of 6.57%, resulting in a ratio of -11.47. These figures indicate that these companies, like NAMS, are not currently generating sufficient returns to cover their cost of capital.
The negative ROIC to WACC ratios for NAMS and its peers reflect the high-risk, high-reward nature of the biopharmaceutical industry. Companies in this sector often require substantial upfront investment in R&D before they can achieve profitability. As these companies progress through clinical trials and move closer to product commercialization, their financial metrics may improve.
